| Bioactivity | VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP[1]. |
| CAS | 1209002-43-6 |
| Formula | C34H42ClN9O4S |
| Molar Mass | 708.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ringer L, et al., VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther. 2010 Aug 15;10(4):320-5. |
VMY-1-103
CAS: 1209002-43-6 F: C34H42ClN9O4S W: 708.27
VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondri
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.